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Introduction {#cam41395-sec-0001}
============

Thyroid cancer is the most common endocrine cancer, accounting for about 1% of all cancers [1](#cam41395-bib-0001){ref-type="ref"}, [2](#cam41395-bib-0002){ref-type="ref"}, and its global incidence is 1.9 per 100,000 among men and 6.1 per 100,000 among women [3](#cam41395-bib-0003){ref-type="ref"}. Multiple factors, including genetic and environmental influences, are associated with thyroid carcinogenesis [1](#cam41395-bib-0001){ref-type="ref"}, [4](#cam41395-bib-0004){ref-type="ref"}, [5](#cam41395-bib-0005){ref-type="ref"}, and well‐known risk factors for thyroid cancer are exposure to ionizing radiation in childhood [4](#cam41395-bib-0004){ref-type="ref"}, [6](#cam41395-bib-0006){ref-type="ref"}, obesity [7](#cam41395-bib-0007){ref-type="ref"}, [8](#cam41395-bib-0008){ref-type="ref"}, and diabetes [9](#cam41395-bib-0009){ref-type="ref"}. In addition, a meta‐analysis including Western countries and Asia also revealed an association between increased height and risk of incidence of thyroid cancer in both sexes [1](#cam41395-bib-0001){ref-type="ref"}, [10](#cam41395-bib-0010){ref-type="ref"}. However, few epidemiological studies have assessed the association between anthropometric factors such as height, weight, or body mass index (BMI) and thyroid cancer among Asian populations.

The aim of this study was to investigate the relationship between anthropometric factors and thyroid cancer incidence, using the Japan Public Health Center (JPHC) Cohort database to obtain information from a study of a large‐scale prospective, population‐based cohort with approximately 100,000 subjects. Our hypothesis was that increasing height or BMI would be associated with the risk of thyroid cancer incidence.

Methods {#cam41395-sec-0002}
=======

Study design, settings, and patients {#cam41395-sec-0003}
------------------------------------

The JPHC Study has been described in detail elsewhere [11](#cam41395-bib-0011){ref-type="ref"}, [12](#cam41395-bib-0012){ref-type="ref"}. In brief, this study combined two cohorts consisting of 140,420 participants (68,722 men and 71,698 women) from 11 public health centers (PHCs). We distributed a self‐administered baseline questionnaire to obtain information regarding anthropometric data, medical history, health screening, lifestyle, dietary habits, and menstrual and reproductive history (for women) from all residents aged 40--59 years in five PHC areas in 1990 (Cohort I). In addition, a similar questionnaire was distributed to all residents aged 40--69 years in six PHC areas between 1993 and 1994 (Cohort II). The JPHC Study protocol was approved by the institutional review board of the National Cancer Center, Tokyo, Japan (approval no.: 13‐021). This study was approved by the Ethical Review Board of Osaka University, Osaka, Japan.

In this study, participants from one PHC area (Katsushika, *n* = 7097) were excluded because of no data on cancer incidence. Participants were also excluded as ineligible because of non‐Japanese nationality (*n* = 51), duplicate registration (*n* = 4), incorrect date of birth (*n* = 7), emigration occurring before the start of the follow‐up period (*n* = 187), or death, moving out of a study area, or loss to follow‐up before the starting point of this study (*n* = 118). In addition, we excluded participants who did not respond to the baseline questionnaire (*n* = 26,587), those who reported a history of any type of cancer (*n* = 2148), those who failed to supply data on height or body weight (*n* = 1,134), those who supplied implausible responses for BMI (\<14 kg/m^2^, or \>40 kg/m^2^) (*n* = 101), and those who supplied implausible responses for height (\<100 cm, or \>200 cm) (*n* = 2). Finally, the number of eligible participants was 102,723 (49,062 men, 53,661 women).

Data collection {#cam41395-sec-0004}
---------------

As a baseline survey, a self‐administered questionnaire was distributed to participants in 1990 for Cohort I and in 1993--1994 for Cohort II. The questionnaire included questions about a variety of lifestyle factors including personal medical history, height, body weight, smoking habits, drinking habits, habits regarding food and beverage intake, physical activity, and reproductive and menstrual factors. With regard to height and body weight, previous studies of the JPHC had compared self‐reported BMI and measured BMI from health checkups using available data and found a very strong correlation between the two (Spearman\'s correlation coefficient of 0.89 in men and 0.90 in women) [13](#cam41395-bib-0013){ref-type="ref"}, [14](#cam41395-bib-0014){ref-type="ref"}.

Follow‐up {#cam41395-sec-0005}
---------

In this study, subjects were followed from the date of responding to the baseline questionnaires until 31 December 2009, in Osaka PHC and 31 December 2010, in the other PHCs. Changes in residence status, including survival, were confirmed annually through the residential registry kept in each municipality of each of the study areas; for individuals who moved out of the area, residence status was confirmed through the municipal office of the area where they had moved. Resident and death registration are required by the Family Registration Law and Basic Residential Register Law in Japan, respectively, and the registers are believed to be complete. Checkup of the resident registry is available to anyone under the Family Registration Law. Information on each cause of death was supplemented by performing a comparison against death certificate files with permission, and the cause of death was defined according to the International Classification of Disease, 10th version (ICD‐10) [15](#cam41395-bib-0015){ref-type="ref"}. Among the available subjects, 14,033 died, 10,185 moved out of the study areas, and 256 were lost to follow‐up within the study follow‐up period.

Study endpoint {#cam41395-sec-0006}
--------------

Cases of thyroid cancer incidence were identified through a specific cancer registry system for the JPHC Study, which was established to collect cancer incidence data on the participants living within the study area through continuous surveillance of hospital records and population‐based cancer registries. Death certificates were used as a source of supplementary information. The site and histological types of each case were coded according to the International Classification of Diseases for Oncology, third edition (ICD‐O‐3, code: C73.9) [16](#cam41395-bib-0016){ref-type="ref"}. The following morphology codes were used to define histologic subtypes: papillary (8050, 8260, 8340--8344, 8350, 8450), follicular (8290, 8330--8335), medullary (8345, 8510--8513), and anaplastic (8020--8021, 8031) [7](#cam41395-bib-0007){ref-type="ref"}, [17](#cam41395-bib-0017){ref-type="ref"}. The incident cases with multiple cancer sites were followed until the date of incident case of thyroid cancer. During 1,695,702 person‐years of follow‐up (mean follow‐up period: 16.5 years), we documented 191 new thyroid cancer cases (37 in men; 154 in women). Diagnosis was confirmed by histologic or cytological examination in 92.7% of cases. The distribution of histologic types was papillary carcinoma in 160 (83.8%), follicular carcinoma in 10 (5.2%), anaplastic carcinoma in 1 (0.01%), and other or unknown histologic types in 20 (10.5%).

Statistical analysis {#cam41395-sec-0007}
--------------------

We conducted all analyses in this study on the basis of sex. Baseline characteristics were expressed by height category (quartile). Baseline characteristics were expressed by height category (quartile) and calculated by analysis of variance for continuous values or chi‐squared test for categorical values to compare the distribution of baseline characteristics according to the height category. The numbers of person‐years in the follow‐up period were counted from the date of responding to the baseline questionnaire to whichever of the following occurred first: date of incidence of thyroid cancer, date of moving out of study areas, date of death, or the end of the follow‐up period.

Hazard ratios (HRs) and 95% confidence intervals (CIs) for each quartile of height, body weight, or BMI and incidence of total thyroid cancer were estimated using the Cox proportional hazards model with adjustment for potential confounders as follows [17](#cam41395-bib-0017){ref-type="ref"}, [18](#cam41395-bib-0018){ref-type="ref"}, [19](#cam41395-bib-0019){ref-type="ref"}. As model 1, we estimated the HRs and 95% CIs adjusted for age group at baseline and PHC areas. As model 2, we estimated the HRs and 95% CIs adjusted for the following factors, which were based on previous studies: smoking habits (never, past, current), regular drinking (yes/no), leisure‐time physical activity (\<1 time/week, ≥1 time/week), past history of diabetes mellitus (yes/no), intake of green tea (3--4 cups/week, 1--2 cups/day, 3--4 cups/day, ≥5 cups/day), intake of seaweed (\<3 days/week, 3--4 days/week, almost daily), health screening in the previous year (yes/no), menopausal status (yes/no) (only for women), and age at menarche (≤13, 14--15, ≥16) (only for women). In model 2, weight and height were mutually adjusted. In the subgroup analysis, HRs and their 95% CIs were also calculated for papillary carcinoma. Furthermore, the subgroup analysis by menopausal status at baseline among women was estimated in consideration of the effects of female sex hormones on thyroid cancer [18](#cam41395-bib-0018){ref-type="ref"}, [19](#cam41395-bib-0019){ref-type="ref"}. Statistical analyses were conducted using STATA version 13 MP (Stata Corp., College Station, TX). All p values were two‐sided, and the significance level was set at a p value less than 0.05.

Results {#cam41395-sec-0008}
=======

Tables [1](#cam41395-tbl-0001){ref-type="table-wrap"} and [2](#cam41395-tbl-0002){ref-type="table-wrap"} show baseline characteristics by quartile of height among men and women, respectively. In both sexes, study participants with greater height were more likely to be young, current smokers, regular drinkers and have a leisure‐time physical activity. In addition, among women, those with greater height were more likely to have young age at menarche and comprised a higher proportion of menopause.

###### 

Baseline characteristics by height in men

                                               Total            Q1               Q2               Q3               Q4               *P* values[a](#cam41395-note-0003){ref-type="fn"}
  -------------------------------------------- ---------------- ---------------- ---------------- ---------------- ---------------- ---------------------------------------------------
  Range                                                         115--160         161--164         165--168         169--199         
  Number                                       49,062           14,716           10,439           12,324           11,583           
  Age, mean (SD)                               51.6 (8.0)       54.7 (7.7)       52.1 (7.7)       50.6 (7.7)       48.4 (7.3)       \<0.001
  Smoking status, *n* (%)                                                                                                           
  Nonsmoker                                    11,839 (24.1)    4,124 (28.0)     2,561 (24.5)     2,762 (22.4)     2,392 (20.7)     \<0.001
  Past smoker                                  11,319 (23.1)    3,401 (23.1)     2,509 (24.0)     2,915 (23.7)     2,494 (21.5)     
  Current smoker                               25,818 (52.6)    7,149 (48.6)     5,357 (51.3)     6,626 (53.8)     6,686 (57.7)     
  Unknown                                      86 (0.2)         42 (0.3)         12 (0.1)         21 (0.2)         11 (0.1)         
  Total                                        49,062 (100.0)   14,716 (100.0)   10,439 (100.0)   12,324 (100.0)   11,583 (100.0)   
  Regular drinker, *n* (%)                                                                                                          
  No                                           8,665 (17.7)     2,906 (19.7)     1,927 (18.5)     2,089 (17.0)     1,743 (15.0)     \<0.001
  Yes                                          33,811 (68.9)    9,569 (65.0)     7,088 (67.9)     8,671 (70.4)     8,483 (73.2)     
  Unknown                                      6,586 (13.4)     2,241 (15.2)     1,424 (13.6)     1,564 (12.7)     1,357 (11.7)     
  Total                                        49,062 (100.0)   14,716 (100.0)   10,439 (100.0)   12,324 (100.0)   11,583 (100.0)   
  Leisure‐time physical activity, *n* (%)                                                                                           
  \<1 time/week                                34,985 (71.3)    11,128 (75.6)    7,468 (71.5)     8,705 (70.6)     7,684 (66.3)     \<0.001
  ≥1 time/week                                 11,984 (24.4)    2,875 (19.5)     2,459 (23.6)     3,152 (25.6)     3,498 (30.2)     
  Unknown                                      2,093 (4.3)      713 (4.8)        512 (4.9)        467 (3.8)        401 (3.5)        
  Total                                        49,062 (100.0)   14,716 (100.0)   10,439 (100.0)   12,324 (100.0)   11,583 (100.0)   
  History of diabetes mellitus, *n* (%)                                                                                             
  No                                           30,165 (61.5)    9,223 (62.7)     6,536 (62.6)     7,623 (61.9)     6,783 (58.6)     \<0.001
  Yes                                          3,182 (6.5)      1,017 (6.9)      731 (7.0)        795 (6.5)        639 (5.5)        
  Unknown                                      15,715 (32.0)    4,476 (30.4)     3,172 (30.4)     3,906 (31.7)     4,161 (35.9)     
  Total                                        49,062 (100.0)   14,716 (100.0)   10,439 (100.0)   12,324 (100.0)   11,583 (100.0)   
  Green tea consumption, *n* (%)                                                                                                    
  ≤3--4 cups/week                              12,577 (25.6)    3,865 (26.3)     2,702 (25.9)     3,126 (25.4)     2,884 (24.9)     \<0.001
  1--2 cups/day                                11,508 (23.5)    3,171 (21.5)     2,393 (22.9)     2,944 (23.9)     3,000 (25.9)     
  3--4 cups/day                                12,859 (26.2)    3,665 (24.9)     2,675 (25.6)     3,330 (27.0)     3,189 (27.5)     
  ≥5 cups/day                                  11,686 (23.8)    3,845 (26.1)     2,584 (24.8)     2,824 (22.9)     2,433 (21.0)     
  Unknown                                      432 (0.9)        170 (1.2)        85 (0.8)         100 (0.8)        77 (0.7)         
  Total                                        49,062 (100.0)   14,716 (100.0)   10,439 (100.0)   12,324 (100.0)   11,583 (100.0)   
  Seaweed consumption, *n* (%)                                                                                                      
  ≤2 days/week                                 27,994 (57.1)    8,206 (55.8)     5,897 (56.5)     6,953 (56.4)     6,938 (59.9)     \<0.001
  3--4 days/week                               13,747 (28.0)    4,169 (28.3)     2,967 (28.4)     3,554 (28.8)     3,057 (26.4)     
  Almost daily                                 6,875 (14.0)     2,141 (14.5)     1,486 (14.2)     1,728 (14.0)     1,520 (13.1)     
  Unknown                                      446              200 (1.4)        89 (0.9)         89 (0.7)         68 (0.6)         
  Total                                        49,062 (100.0)   14,716 (100.0)   10,439 (100.0)   12,324 (100.0)   11,583 (100.0)   
  Health screening in previous year, *n* (%)                                                                                        
  No                                           9,603 (19.6)     2,815 (19.1)     1,930 (18.5)     2,502 (20.3)     2,356 (20.3)     \<0.001
  Yes                                          39,162 (79.8)    11,771 (80.0)    8,446 (80.9)     9,752 (79.1)     9,193 (79.4)     
  Unknown                                      297 (0.6)        130 (0.9)        63 (0.6)         70 (0.6)         34 (0.3)         
  Total                                        49,062 (100.0)   14,716 (100.0)   10,439 (100.0)   12,324 (100.0)   11,583 (100.0)   

Q, quartile, SD, standard deviation.

*P*‐values were calculated by analysis of variance for continuous values or chi‐squared test for categorical values to compare the distribution of baseline characteristics according to the height category.
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###### 

Baseline characteristics by height in women

                                               Total            Q1               Q2               Q3               Q4               *P* values[a](#cam41395-note-0005){ref-type="fn"}
  -------------------------------------------- ---------------- ---------------- ---------------- ---------------- ---------------- ---------------------------------------------------
  Range                                                         110--148         149--152         153--156         157--198         
  Number                                       53,661           13,727           15,733           13,478           10,723           
  Age, mean (SD)                               51.9 (8.0)       55.0 (7.9)       52.4 (7.8)       50.6 (7.6)       48.7 (7.4)       \<0.001
  Smoking status, *n* (%)                                                                                                           
  Nonsmoker                                    49,041 (91.4)    12,803 (93.3)    14,503 (92.2)    12,238 (90.8)    9,497 (88.6)     \<0.001
  Past smoker                                  822 (1.5)        157 (1.1)        234 (1.5)        205 (1.5)        226 (2.1)        
  Current smoker                               3,582 (6.7)      698 (5.1)        927 (5.9)        987 (7.3)        970 (9.0)        
  Unknown                                      216 (0.4)        69 (0.5)         69 (0.4)         48 (0.4)         30 (0.3)         
  Total                                        53,661 (100.0)   13,727 (100.0)   15,733 (100.0)   13,478 (100.0)   10,723 (100.0)   
  Regular drinker, *n* (%)                                                                                                          
  No                                           22,094 (41.2)    5,817 (42.4)     6,738 (42.8)     5,489 (40.7)     4,050 (37.8)     \<0.001
  Yes                                          7,139 (13.3)     1,213 (8.8)      1,920 (12.2)     1,990 (14.8)     2,016 (18.8)     
  Unknown                                      24,428 (45.5)    6,697 (48.8)     7,075 (45.0)     5,999 (44.5)     4,657 (43.4)     
  Total                                        53,661 (100.0)   13,727 (100.0)   15,733 (100.0)   13,478 (100.0)   10,723 (100.0)   
  Leisure‐time physical activity, *n* (%)                                                                                           
  \<1 time/week                                41,096 (76.6)    10,801 (78.7)    12,207 (77.6)    10,257 (76.1)    7,831 (73.0)     \<0.001
  ≥1 time/week                                 10,203 (19.0)    2,224 (16.2)     2,815 (17.9)     2,669 (19.8)     2,495 (23.3)     
  Unknown                                      2,362 (4.4)      702 (5.1)        711 (4.5)        552 (4.1)        397 (3.7)        
  Total                                        53,661 (100.0)   13,727 (100.0)   15,733 (100.0)   13,478 (100.0)   10,723 (100.0)   
  History of diabetes mellitus, *n* (%)                                                                                             
  No                                           31,240 (58.2)    8,410 (61.3)     9,467 (60.2)     7,731 (57.4)     5,632 (52.5)     \<0.001
  Yes                                          1,589 (3.0)      521 (3.8)        468 (3.0)        343 (2.5)        257 (2.4)        
  Unknown                                      20,832 (38.8)    4,796 (34.9)     5,798 (36.9)     5,404 (40.1)     4,834 (45.1)     
  Total                                        53,661 (100.0)   13,727 (100.0)   15,733 (100.0)   13,478 (100.0)   10,723 (100.0)   
  Green tea consumption, *n* (%)                                                                                                    
  ≤3--4 cups/week                              12,975 (24.2)    3,503 (25.5)     3,861 (24.5)     3,143 (23.3)     2,468 (23.0)     \<0.001
  1--2 cups/day                                11,190 (20.9)    2,680 (19.5)     3,198 (20.3)     2,897 (21.5)     2,415 (22.5)     
  3--4 cups/day                                14,810 (27.6)    3,669 (26.7)     4,348 (27.6)     3,782 (28.1)     3,011 (28.1)     
  ≥5 cups/day                                  14,167 (26.4)    3,716 (27.1)     4,175 (26.5)     3,544 (26.3)     2,732 (25.5)     
  Unknown                                      519 (1.0)        159 (1.2)        151 (1.0)        112 (0.8)        97 (0.9)         
  Total                                        53,661 (100.0)   13,727 (100.0)   15,733 (100.0)   13,478 (100.0)   10,723 (100.0)   
  Seaweed consumption, *n* (%)                                                                                                      
  ≤2 days/week                                 24,762 (46.1)    6,233 (45.4)     7,112 (45.2)     6,230 (46.2)     5,187 (48.4)     \<0.001
  3--4 days/week                               18,183 (33.9)    4,735 (34.5)     5,312 (33.8)     4,640 (34.4)     3,496 (32.6)     
  Almost daily                                 10,205 (19.0)    2,565 (18.7)     3,150 (20.0)     2,511 (18.6)     1,979 (18.5)     
  Unknown                                      511 (1.0)        194 (1.4)        159 (1.0)        97 (0.7)         61 (0.6)         
  Total                                        53,661 (100.0)   13,727 (100.0)   15,733 (100.0)   13,478 (100.0)   10,723 (100.0)   
  Health screening in previous year, *n* (%)                                                                                        
  No                                           10,882 (20.3)    2,186 (15.9)     3,122 (19.8)     2,907 (21.6)     2,667 (24.9)     \<0.001
  Yes                                          42,437 (79.1)    11,411 (83.1)    12,510 (79.5)    10,510 (78.0)    8,006 (74.7)     
  Unknown                                      342 (0.6)        130 (0.9)        101 (0.6)        61 (0.5)         50 (0.5)         
  Total                                        53,661 (100.0)   13,727 (100.0)   15,733 (100.0)   13,478 (100.0)   10,723 (100.0)   
  Menopausal status, *n* (%)                                                                                                        
  No                                           21,646 (40.3)    3,519 (25.6)     5,839 (37.1)     6,256 (46.4)     6,032 (56.3)     \<0.001
  Yes                                          30,253 (56.4)    9,608 (70.0)     9,366 (59.5)     6,840 (50.7)     4,439 (41.4)     
  Unknown                                      1,762 (3.3)      600 (4.4)        528 (3.4)        382 (2.8)        252 (2.4)        
  Total                                        53,661 (100.0)   13,727 (100.0)   15,733 (100.0)   13,478 (100.0)   10,723 (100.0)   
  Age at menarche, *n* (%)                                                                                                          
  ≤13                                          14,267 (26.6)    2,548 (18.6)     3,883 (24.7)     4,074 (30.2)     3,762 (35.1)     \<0.001
  14--15                                       23,323 (43.5)    5,481 (39.9)     6,949 (44.2)     6,068 (45.0)     4,825 (45.0)     
  ≥16                                          14,599 (27.2)    5,286 (38.5)     4,464 (28.4)     2,960 (22.0)     1,889 (17.6)     
  Unknown                                      1,472 (2.7)      412 (3.0)        437 (2.8)        376 (2.8)        247 (2.3)        
  Total                                        53,661 (100.0)   13,727 (100.0)   15,733 (100.0)   13,478 (100.0)   10,723 (100.0)   

Q, quartile, SD, standard deviation.

*P*‐values were calculated by analysis of variance for continuous values or chi‐squared test for categorical values to compare the distribution of baseline characteristics according to the height category.

John Wiley & Sons, Ltd

Table [3](#cam41395-tbl-0003){ref-type="table-wrap"} shows the risk of total thyroid cancer according to anthropometric features in both sexes. In the multivariable‐adjusted model (model 2), compared with the male group with height ≤160 cm, the HRs of the male groups with height 165--168 cm and ≥169 cm were 3.92 (95% CI 1.33--11.55, *P* = 0.013) and 4.24 (95% CI 1.32--13.61, *P* = 0.015), respectively, and the HR per 5‐cm increase in height was 1.12 (95% CI 1.06--1.18, *P* \< 0.001). In analysis to exclude the incidence of thyroid cancer within the first 3 years of follow‐up, a similar association was observed between greater height and incidence of thyroid cancer (data not shown). However, there were no associations between incidence of thyroid cancer and either weight or BMI. No significant associations were observed between anthropometric features and total thyroid cancer risk in women.

###### 

Hazard ratios of total thyroid cancer according to anthropometric features in both sexes

                            No. cases   Person‐years   Incidence   Crude HR   95%CI         *P* values   HR1    95%CI         *P* values   HR2    95%CI         *P* values
  ------------------------- ----------- -------------- ----------- ---------- ------------- ------------ ------ ------------- ------------ ------ ------------- ------------
  Men                                                                                                                                                           
  Height, quintile (cm)                                                                                                                                         
  ≤160                      5           237,452        2.11        1.00       (Reference)                1.00   (Reference)                1.00   (Reference)   
  161--164                  5           169,805        2.94        1.39       0.40--4.81    0.601        1.60   0.46--5.58    0.459        1.51   0.43--5.30    0.524
  165--168                  14          197,846        7.08        3.36       1.21--9.32    0.020        4.23   1.49--12.01   0.007        3.92   1.33--11.55   0.013
  ≥169                      13          181,246        7.17        3.43       1.22--9.63    0.019        4.91   1.67--14.39   0.004        4.24   1.32--13.61   0.015
  per 5‐cm increase                                                1.10       1.04--1.15    \<0.001      1.12   1.06--1.17    \<0.001      1.12   1.06--1.18    \<0.001
  Weight, quintile (kg)                                                                                                                                         
  ≤57                       6           204,233        2.94        1.00       (Reference)                1.00   (Reference)                1.00   (Reference)   
  58--63                    5           216,350        2.31        0.78       0.24--2.55    0.680        0.84   0.26--2.76    0.773        0.62   0.19--2.06    0.438
  64--69                    14          175,230        7.99        2.69       1.03--7.00    0.042        3.16   1.20--8.30    0.020        1.82   0.67--4.94    0.237
  ≥70                       12          190,536        6.30        2.13       0.80--5.67    0.131        2.76   1.02--7.50    0.046        1.18   0.40--3.44    0.764
  per 5‐kg increase                                                1.03       1.00--1.07    0.056        1.04   1.01--1.08    0.013        1.01   0.97--1.05    0.733
  BMI, quintile (kg/m^2^)                                                                                                                                       
  ≤21.51                    9           194,240        4.63        1.00       (Reference)                1.00   (Reference)                1.00   (Reference)   
  21.52--23.37              11          193,708        5.68        1.21       0.50--2.93    0.667        1.23   0.51--2.98    0.643        1.20   0.49--2.90    0.688
  23.37--25.27              6           201,538        2.98        0.63       0.23--1.78    0.386        0.67   0.24--1.89    0.447        0.62   0.22--1.77    0.375
  ≥25.28                    11          196,862        5.59        1.19       0.49--2.87    0.699        1.33   0.54--3.26    0.529        1.17   0.47--2.90    0.732
  per 5‐kg/m^2^ increase                                           0.95       0.86--1.06    0.375        0.96   0.87--1.07    0.509        0.95   0.85--1.06    0.364
  Women                                                                                                                                                         
  Height, quintile (cm)                                                                                                                                         
  ≤148                      37          235,738        15.70       1.00       (Reference)                1.00   (Reference)                1.00   (Reference)   
  149--152                  43          269,190        15.97       1.02       0.66--1.58    0.938        0.99   0.64--1.54    0.971        0.96   0.61--1.50    0.842
  153--156                  41          227,575        18.02       1.15       0.74--1.79    0.543        1.12   0.71--1.76    0.636        1.05   0.65--1.68    0.842
  ≥157                      33          176,849        18.66       1.19       0.74--1.90    0.471        1.18   0.72--1.93    0.511        1.07   0.63--1.82    0.794
  per 5‐cm increase                                                1.01       0.98--1.04    0.454        1.01   0.98--1.04    0.513        1.00   0.97--1.04    0.807
  Weight, quintile (kg)                                                                                                                                         
  ≤49                       37          245,993        15.04       1.00       (Reference)                1.00   (Reference)                1.00   (Reference)   
  50--53                    27          214,117        12.61       0.84       0.51--1.38    0.489        0.82   0.50--1.35    0.435        0.81   0.49--1.34    0.416
  54--59                    45          237,858        18.92       1.26       0.81--1.95    0.299        1.22   0.79--1.88    0.376        1.21   0.77--1.89    0.416
  ≥60                       45          211,385        21.29       1.42       0.92--2.19    0.116        1.36   0.88--2.11    0.162        1.36   0.85--2.17    0.197
  per 5‐kg increase                                                1.02       1.00--1.04    0.119        1.01   0.99--1.03    0.165        1.01   0.99--1.04    0.218
  BMI, quintile (kg/m^2^)                                                                                                                                       
  ≤21.23                    33          221,944        14.87       1.00       (Reference)                1.00   (Reference)                1.00   (Reference)   
  21.24--23.11              36          228,454        15.76       1.06       0.66--1.70    0.804        1.04   0.65--1.67    0.874        1.03   0.64--1.65    0.911
  23.12--25.31              36          230,207        15.64       1.05       0.66--1.69    0.827        1.03   0.64--1.65    0.910        1.02   0.63--1.64    0.935
  ≥25.32                    49          228,747        21.42       1.44       0.93--2.24    0.103        1.43   0.91--2.24    0.120        1.43   0.91--2.24    0.122
  per 5‐kg/m^2^ increase                                           1.02       0.97--1.07    0.397        1.02   0.97--1.07    0.451        1.02   0.97--1.07    0.459

BMI, body mass index; HR, hazard rate; CI, confidence interval.

HR1: Adjusted for age and public health center area.

HR2: Adjusted for age, public health center area, smoking status, alcohol drinking, leisure‐time physical activity, history of diabetes mellitus, green tea consumption, seaweed consumption, health screening in the previous year, menopausal status (only for women), and age at menarche (only for women). Weight and height were mutually adjusted.
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Table [4](#cam41395-tbl-0004){ref-type="table-wrap"} shows the risk of papillary carcinoma according to anthropometric features in both sexes. In the multivariable‐adjusted model (model 2), the HRs for the groups of men with height 165--168 cm and ≥169 cm with the reference group of men ≤160 cm were 3.63 (95% CI 1.09--12.13, *P* = 0.036) and 4.05 (95% CI 1.12--14.71, *P* = 0.033), respectively, and the HR per 5‐cm increase in height was 1.12 (95% CI 1.05--1.19, *P* \< 0.001). In analysis to exclude the incidence of papillary thyroid cancer within the first 3 years of follow‐up, a similar association was observed between greater height and incidence of papillary thyroid cancer (data not shown). However, there was no association between incidence of thyroid cancer and either weight or BMI. Neither height nor weight nor BMI was significantly associated with increased risk of papillary carcinoma in women.

###### 

Hazard ratios of papillary carcinoma according to anthropometric features in both sexes

                            No. cases   Person‐years   Incidence   Crude HR   95%CI         *P* values   HR1    95%CI         *P* values   HR2    95%CI         *P* values
  ------------------------- ----------- -------------- ----------- ---------- ------------- ------------ ------ ------------- ------------ ------ ------------- ------------
  Men                                                                                                                                                           
  Height, quintile (cm)                                                                                                                                         
  ≤160                      4           237,452        1.68        1.00       (Reference)                1.00   (Reference)                1.00   (Reference)   
  161--164                  5           169,805        2.94        1.74       0.47--6.48    0.409        1.97   0.52--7.39    0.317        1.81   0.48--6.90    0.382
  165--168                  11          197,846        5.56        3.29       1.05--10.33   0.041        3.95   1.23--12.71   0.021        3.63   1.09--12.13   0.036
  ≥169                      11          181,246        6.07        3.62       1.15--11.35   0.028        4.78   1.45--15.76   0.010        4.05   1.12--14.71   0.033
  per 5‐cm increase                                                1.10       1.04--1.16    \<0.001      1.12   1.06--1.18    \<0.001      1.12   1.05--1.19    \<0.001
  Weight, quintile (kg)                                                                                                                                         
  ≤57                       6           204,233        2.94        1.00       (Reference)                1.00   (Reference)                1.00   (Reference)   
  58--63                    3           216,350        1.39        0.47       0.12--1.87    0.282        0.50   0.12--2.00    0.326        0.36   0.09--1.47    0.156
  64--69                    12          175,230        6.85        2.31       0.87--6.15    0.094        2.69   1.00--7.23    0.051        1.51   0.54--4.22    0.431
  ≥70                       10          190,536        5.25        1.77       0.64--4.87    0.268        2.28   0.81--6.43    0.117        0.95   0.31--2.90    0.928
  per 5‐kg increase                                                1.03       1.00--1.07    0.089        1.04   1.01--1.08    0.025        1.01   0.96--1.05    0.798
  BMI, quintile (kg/m^2^)                                                                                                                                       
  ≤21.51                    8           194,240        4.12        1.00       (Reference)                1.00   (Reference)                1.00   (Reference)   
  21.52--23.37              8           193,708        4.13        0.99       0.37--2.65    0.990        1.01   0.38--2.71    0.977        0.98   0.37--2.62    0.970
  23.37--25.27              5           201,538        2.48        0.60       0.19--1.82    0.363        0.64   0.21--1.96    0.432        0.60   0.19--1.84    0.369
  ≥25.28                    10          196,862        5.08        1.22       0.48--3.09    0.676        1.43   0.56--3.67    0.457        1.26   0.48--3.27    0.637
  per 5‐kg/m^2^ increase                                           0.94       0.83--1.05    0.269        0.95   0.84--1.07    0.406        0.94   0.83--1.06    0.294
  Women                                                                                                                                                         
  Height, quintile (cm)                                                                                                                                         
  ≤148                      31          235,738        13.15       1.00       (Reference)                1.00   (Reference)                1.00   (Reference)   
  149--152                  35          269,190        13.00       0.99       0.61--1.60    0.964        0.94   0.58--1.53    0.794        0.89   0.55--1.46    0.658
  153--156                  34          227,575        14.94       1.14       0.70--1.85    0.604        1.06   0.64--1.74    0.832        0.97   0.58--1.63    0.912
  ≥157                      29          176,849        16.40       1.25       0.75--2.07    0.388        1.17   0.69--1.99    0.562        1.04   0.59--1.84    0.887
  per 5‐cm increase                                                1.02       0.99--1.05    0.211        1.02   0.98--1.05    0.336        1.01   0.98--1.05    0.581
  Weight, quintile (kg)                                                                                                                                         
  ≤49                       30          245,993        12.20       1.00       (Reference)                1.00   (Reference)                1.00   (Reference)   
  50--53                    23          214,117        10.74       0.88       0.51--1.52    0.647        0.86   0.50--1.48    0.585        0.84   0.48--1.45    0.523
  54--59                    37          237,858        15.56       1.27       0.79--2.06    0.323        1.23   0.76--1.99    0.402        1.19   0.72--1.95    0.503
  ≥60                       39          211,385        18.45       1.51       0.94--2.44    0.088        1.46   0.90--2.35    0.122        1.40   0.84--2.33    0.199
  per 5‐kg increase                                                1.02       0.99--1.04    0.144        1.01   0.99--1.04    0.195        1.01   0.99--1.04    0.336
  BMI, quintile (kg/m^2^)                                                                                                                                       
  ≤21.23                    28          221,944        12.62       1.00       (Reference)                1.00   (Reference)                1.00   (Reference)   
  21.24--23.11              31          228,454        13.57       1.08       0.65--1.79    0.780        1.06   0.64--1.78    0.810        1.04   0.62--1.74    0.871
  23.12--25.31              30          230,207        13.03       1.03       0.62--1.73    0.904        1.03   0.61--1.72    0.922        1.01   0.60--1.70    0.964
  ≥25.32                    40          228,747        17.49       1.39       0.85--2.25    0.186        1.42   0.87--2.32    0.166        1.40   0.85--2.29    0.183
  per 5‐kg/m^2^ increase                                           1.01       0.96--1.06    0.608        1.01   0.96--1.07    0.597        1.01   0.96--1.07    0.620

BMI, body mass index; HR, hazard rate; CI, confidence interval.

HR1: Adjusted for age and public health center area.

HR2: Adjusted for age, public health center area, smoking status, alcohol drinking, leisure‐time physical activity, history of diabetes mellitus, green tea consumption, seaweed consumption, health screening in the previous year, menopausal status (only for women), and age at menarche (only for women). Weight and height were mutually adjusted.
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The risk of total thyroid cancer according to anthropometric features by menopausal status among women is noted in Table [5](#cam41395-tbl-0005){ref-type="table-wrap"}. Irrespective of menopausal status, each quartile of anthropometric features was not significantly associated with increased risk of total thyroid cancer among women.

###### 

Hazard ratios of total thyroid cancer according to anthropometric features in both premenopausal women and postmenopausal women

                            Premenopausal women   Postmenopausal women                                                   
  ------------------------- --------------------- ---------------------- ------------- ------- ---- ------ ------------- -------
  Height, quintile (cm)                                                                                                  
  ≤148                      14                    1.00                   (Reference)           20   1.00   (Reference)   
  149--152                  21                    0.87                   0.40--1.90    0.734   20   0.81   0.38--1.71    0.583
  153--156                  25                    1.05                   0.49--2.25    0.904   16   1.03   0.46--2.26    0.951
  ≥157                      13                    0.68                   0.28--1.62    0.383   17   1.58   0.68--3.66    0.288
  per 5‐cm increase                               1.00                   0.95--1.05    0.887        1.01   0.96--1.08    0.511
  Weight, quintile (kg)                                                                                                  
  ≤49                       16                    1.00                   (Reference)           19   1.00   (Reference)   
  50--53                    16                    1.25                   0.58--2.73    0.569   11   0.72   0.31--1.69    0.455
  54--59                    18                    1.16                   0.53--2.53    0.712   23   1.15   0.55--2.43    0.707
  ≥60                       23                    1.78                   0.83--3.83    0.140   20   1.13   0.51--2.50    0.766
  per 5‐kg increase                               1.03                   0.99--1.06    0.139        1.01   0.96--1.08    0.567
  BMI, quintile (kg/m^2^)                                                                                                
  ≤21.23                    17                    1.00                   (Reference)           14   1.00   (Reference)   
  21.24--23.11              17                    0.88                   0.42--1.86    0.740   18   1.22   0.54--2.76    0.628
  23.12--25.31              16                    1.01                   0.48--2.11    0.984   17   1.16   0.51--2.63    0.722
  ≥25.32                    23                    1.52                   0.75--3.05    0.243   24   1.20   0.53--2.70    0.659
  per 5‐kg/m^2^ increase                          1.04                   0.96--1.12    0.326        0.99   0.96--1.08    0.627

BMI, body mass index; HR, hazard rate; CI, confidence interval.

HR: Adjusted for age, public health center area, smoking status, alcohol drinking, leisure‐time physical activity, history of diabetes mellitus, green tea consumption, seaweed consumption, health screening in the previous year, and age at menarche.
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Discussion {#cam41395-sec-0009}
==========

Using data from a large‐scale population‐based cohort in Japan, we observed that the risk of thyroid cancer incidence among men significantly increased with increasing height. However, there were no associations between either weight or BMI and risk of thyroid cancer incidence among men. On the other hand, neither height nor weight nor BMI was associated with the risk of thyroid cancer incidence among women.

The results of this study underscored the positive association between height and thyroid cancer incidence in men, with the finding of significant increases in HRs per 5‐cm increase in height. Previous studies, conducted mainly in Europe and the United States, have shown conflicting results regarding the association between height and incidence of thyroid cancer. Some cohort studies have shown a positive association between height and thyroid cancer incidence in both sexes [20](#cam41395-bib-0020){ref-type="ref"}, [21](#cam41395-bib-0021){ref-type="ref"}, [22](#cam41395-bib-0022){ref-type="ref"}, whereas other cohort studies have reported no association between height and thyroid cancer incidence among either men or women [23](#cam41395-bib-0023){ref-type="ref"}, [24](#cam41395-bib-0024){ref-type="ref"}, [25](#cam41395-bib-0025){ref-type="ref"}. The association between height and thyroid cancer incidence could be explained partially by the effect of insulin‐like growth factor (IGF‐1). Previous studies reported a positive association between the level of IGF‐1 and the risk of thyroid cancer incidence [1](#cam41395-bib-0001){ref-type="ref"}, [26](#cam41395-bib-0026){ref-type="ref"}. Higher IGF‐1 levels promote mutation in various cell lines including thyroid cells [1](#cam41395-bib-0001){ref-type="ref"}, [21](#cam41395-bib-0021){ref-type="ref"}, [26](#cam41395-bib-0026){ref-type="ref"}, [27](#cam41395-bib-0027){ref-type="ref"} and contribute to increased risk of cancer incidence by stimulating cell proliferation, adhesion, and migration, and by inhibiting apoptosis [1](#cam41395-bib-0001){ref-type="ref"}, [21](#cam41395-bib-0021){ref-type="ref"}, [27](#cam41395-bib-0027){ref-type="ref"}. Importantly, IGF‐1 plays an important role in the regulation of postnatal growth, and taller individuals have higher levels of IGF‐1 in childhood and adolescence. Thus, the risk of thyroid cancer incidence might show a particular increase in taller men [1](#cam41395-bib-0001){ref-type="ref"}, [26](#cam41395-bib-0026){ref-type="ref"}. In a previous study investigating the association between height and several cancers, the risk of cancer by height per 5 cm was highest in thyroid cancer among men [20](#cam41395-bib-0020){ref-type="ref"}, and thyroid cancer might be more strongly influenced by height than cancers in other sites.

Some studies have reported that the risk of thyroid cancer incidence demonstrated an increase among women with greater height in the same way as among men [20](#cam41395-bib-0020){ref-type="ref"}, [21](#cam41395-bib-0021){ref-type="ref"}, [22](#cam41395-bib-0022){ref-type="ref"}. On the other hand, it has also been reported that the incidence of thyroid cancer is not associated with height among women in Western countries, as our study indicated [23](#cam41395-bib-0023){ref-type="ref"}, [24](#cam41395-bib-0024){ref-type="ref"}, [25](#cam41395-bib-0025){ref-type="ref"}. In this study, the lack of association between height and thyroid cancer incidence in Japanese women might be explanted by lower and narrower range of height among women [13](#cam41395-bib-0013){ref-type="ref"}. On the other hand, the risk of thyroid cancer incidence has been found to increase with greater height among Korean women, who have heights similar to Japanese women [20](#cam41395-bib-0020){ref-type="ref"}. Thus, the mechanism between height and thyroid cancer incidence remains under debate, and further evaluation of anthropometric factors related to thyroid cancer incidence is required among women globally, including in Asia.

Regarding BMI, obesity was not associated with risk of thyroid cancer incidence, irrespective of sex. This result was inconsistent with previous reports including cohort studies and meta‐analysis [7](#cam41395-bib-0007){ref-type="ref"}, [8](#cam41395-bib-0008){ref-type="ref"}, [28](#cam41395-bib-0028){ref-type="ref"}, [29](#cam41395-bib-0029){ref-type="ref"}. Various hypotheses have been offered to explain the positive association between obesity and incidence of thyroid cancer. First, thyroid‐stimulating hormone (TSH) levels have been positively associated with obesity, and exposure to higher TSH levels via obesity leads to increasing risk of thyroid goiter and subsequent thyroid cancer incidence [30](#cam41395-bib-0030){ref-type="ref"}. Second, leptin levels were higher in patients with thyroid cancer compared to healthy subjects in a case--control study [31](#cam41395-bib-0031){ref-type="ref"}. Leptin levels are associated with regulation of energy balance and insulin action [32](#cam41395-bib-0032){ref-type="ref"}, and obesity positively affects levels of adipokines including leptin [33](#cam41395-bib-0033){ref-type="ref"}. Leptin has also been shown to enhance the migration of papillary thyroid cancer [34](#cam41395-bib-0034){ref-type="ref"}. The proportion of participants with BMI ≥30 in our study was only 3%; however, in Western countries, it has been found to be 7--12% [24](#cam41395-bib-0024){ref-type="ref"}, [35](#cam41395-bib-0035){ref-type="ref"}, [36](#cam41395-bib-0036){ref-type="ref"}. As the prevalence of BMI ≥30 was lower in Japanese [14](#cam41395-bib-0014){ref-type="ref"} than in European [35](#cam41395-bib-0035){ref-type="ref"} or American individuals [36](#cam41395-bib-0036){ref-type="ref"}, the effect of BMI on the risk of thyroid cancer incidence might be small in this study.

Furthermore, anthropometric factors by menopausal status were not associated with the risk of thyroid cancer incidence among women. Both epidemiological and experimental studies suggest that steroid hormones may play a role in the etiology of thyroid cancer [37](#cam41395-bib-0037){ref-type="ref"}, [38](#cam41395-bib-0038){ref-type="ref"}, [39](#cam41395-bib-0039){ref-type="ref"}, [40](#cam41395-bib-0040){ref-type="ref"}. A previous investigation in the JPHC Study exploring the association between reproductive factors and thyroid cancer reported that lower age at menarche reduced the risk of thyroid cancer among premenopausal women, and surgical menopause increased the risk of thyroid cancer among postmenopausal women [19](#cam41395-bib-0019){ref-type="ref"}. However, in our analyses, mean age at menarche did not differ among the height groups, and the impact of this factor was small. On the other hand, a previous study of the association between female hormones and height reported that the beginning of menstruation with secretion of estrogen could close the epiphyseal cartilage and terminate height increases [41](#cam41395-bib-0041){ref-type="ref"}, [42](#cam41395-bib-0042){ref-type="ref"}. The mechanism of the interaction between female hormones and height, as well as the effect of these factors on thyroid cancer incidence, remains unclear, and further studies will be needed to confirm the associations.

Limitations {#cam41395-sec-0010}
===========

This study has several limitations. First, we did not measure height and weight, and the study used self‐reported questionnaires. However, self‐reported height and weight would be less affected by recall bias in our study, because the correlation between self‐reported BMI and measured BMI was strong, as described in the Methods. Second, we did not obtain information regarding exposure to external radiation, which is one of the well‐known risk factors for thyroid cancer incidence [4](#cam41395-bib-0004){ref-type="ref"}, [6](#cam41395-bib-0006){ref-type="ref"}. Third, information on socioeconomic status was not obtained from all participants. Socioeconomic status may affect the frequencies which participants receive health screening, and it could, therefore, also be linked to the detection of thyroid cancer and, thus, be a source of detection bias [18](#cam41395-bib-0018){ref-type="ref"}. Fourth, unknown confounding factors might affect the association between thyroid cancer incidence and anthropometric factors. Fifth, the number of cases of thyroid cancer in men was small, and results should be replicated in a larger population.

Conclusion {#cam41395-sec-0011}
==========

In this study population, greater height was associated with an increased risk of thyroid cancer incidence in Japanese men. However, the risk of thyroid cancer was not associated with anthropometric factors in Japanese women.
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